Results 111 to 120 of about 667,241 (301)
Pulmonary Hypertension Caused by Pulmonary Venous Hypertension [PDF]
The effect of pulmonary venous hypertension (PVH) on the pulmonary circulation is extraordinarily variable, ranging from no impact on pulmonary vascular resistance (PVR) to a marked increase. The reasons for this are unknown. Both acutely reversible pulmonary vasoconstriction and pathological remodeling (especially medial hypertrophy and intimal ...
openaire +3 more sources
Group 1 of PAH patients encompasses patients with a diverse underlying etiological condition, having histological modifications that can affect gas exchange across the alveolar-capillary membrane, as reflected by decreased DLCO.
Effrosyni Dima +12 more
doaj +1 more source
Geriatric asthmatics exhibit more comorbidities, poorer lung function, higher neutrophil ratios, and elevated CRP levels. ABSTRACT Objective The research analyzed the clinical characteristics of geriatric and nongeriatric asthma cases, aiming to provide new insights into the diagnosis and management of geriatric asthma for clinicians.
Mengxia Gu +4 more
wiley +1 more source
Pulmonary arterial hypertension (PAH) must be classified into primary pulmonary hypertension and PAH related to other diseases such as collagen vascular diseases, HIV infection or portal hypertension. PAH must also be differentiated from other entities, in particular pulmonary hypertension secondary to thromboembolic diseases, requiring specific ...
openaire +3 more sources
ABSTRACT Background/Objectives Postoperative complications following pancreaticoduodenectomy (PD) remain high, particularly in patients with soft pancreatic texture. Abdominal aortic calcification volume (AACV), a surrogate marker of systemic arteriosclerosis, has been associated with increased surgical risk in lower gastrointestinal procedures ...
Masaki Horiuchi +9 more
wiley +1 more source
The role of endothelin-1 in pulmonary arterial hypertension. [PDF]
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core +1 more source
Targeted vasopeptide therapies have significantly advanced the management of pulmonary arterial hypertension (PAH). However, due to insufficient preclinical evidence regarding the involvement of the endothelin-1 (ET-1) pathway in chronic thromboembolic ...
Benchenouf Feriel +16 more
doaj +1 more source
DDAH1 regulates apoptosis and angiogenesis in human fetal pulmonary microvascular endothelial cells
Nitric Oxide (NO) is an endogenous pulmonary vasodilator produced by endothelial NO synthase (eNOS). Asymmetric dimethyl L‐arginine (ADMA) is an endogenous inhibitor of eNOS activity.
Jennifer K. Trittmann +3 more
doaj +1 more source
A reliable and effective risk prediction model for mortality and morbidity in elderly patients undergoing gastroenterological surgeries was developed and validated. Geriatric‐specific risk factors, including the newly added variables in the NCD registry, along with age, were identified as significant contributors to the model. ABSTRACT Aim As the aging
Naoya Sato +11 more
wiley +1 more source
Sarcopenia in Patients with Chronic Thromboembolic Pulmonary Hypertension
Background: Sarcopenia, or loss of skeletal muscle mass, has been associated with poor outcomes (e.g., functional decline, increased mortality, and low quality of life), but its role in CTEPH remains unclear.
Steven Hopkins +8 more
doaj +1 more source

